MARKETS / BALCAO / VYCO
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Vycor Medical, Inc. VYCO

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.9M
▲ 17.2% vs FY2024
EPS · FY25
$-0.01
Dividend / sh · FY25
Payout · FY25
ROE · FY25
Net margin · FY25
-3.9%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.9M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.00050.0010.00150.0020.0-0.0201020132016201920222025
0.00050.0010.00150.0020.0-0.02016201920222025

The company lost 4 cents on every revenue dollar this year.

Per share
USD -0.01
Diluted EPS, FY2025
EPS
0.40.81.2-0.01201020132016201920222025
0.40.81.2-0.012016201920222025

The company pays no cash dividend.

Profitability
Return on equity, FY2025
ROE
0.250.50.751201020132016201920222025
0.250.50.7512016201920222025
Operating margin1.8%
Net margin-3.9%
Return on assets-7.9%

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+10.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.1%
+10.3%
+5.0%
+12.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.03B
Shares outstanding, FY2025
0.720.03201020132016201920222025
0.010.032016201920222025
Change, 5 years+21.7%
Change, 10 years

The share count grew 22% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 830,420.00
total assets, end of FY2025
Total assetsUSD 830,420.00
EquityUSD -4.1M
CashUSD 86,982.00
Current ratio0.12×

Equity funds -492% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
·
·
0.0
0.0
·
·
·
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.01
−0.01
−0.01
−0.02
−0.03
−0.04
−0.05
−0.08
−0.10
−0.17
−0.20
−0.39
−0.39
−0.52
−0.92
−0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
−210.5
·
·
·
−5370.7
−295.2
−103.2
·
·
·
−991.4
−2236.2
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.72

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
63 of 63
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed